
Immuno-Oncology
Latest News
Advertisement
Latest Videos

CME Content
Advertisement
More News












The explosion of new checkpoint immunotherapy drugs has changed the paradigm of care for patients with urothelial carcinoma, the most common form of bladder cancer.











Following treatment with single-agent nivolumab (Opdivo), patients with head and neck squamous cell carcinoma saw improved or stable quality of life scores.

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

The future of treatment for ovarian cancer may lie in immunotherapy combinations with PARP inhibitors or checkpoint inhibitors.
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5
















































